Globe Life has just delivered its July 22 earnings print, and the question now shifts from what analysts expected to what the numbers actually say — with the stock up 3% on the week and options traders positioned as bullishly as they have been all year.
The options market tells the clearest story on sentiment heading into the report. The put/call ratio dropped to 0.16 on Tuesday, well below its 20-day average of 0.24 and near the bottom of its 52-week range of 0.08–0.42. That is one of the least defensive readings of the past year — traders were buying calls, not hedging with puts. The shift is sharp: through the first two weeks of July the PCR held around 0.33–0.34, then collapsed in the final days before the print. That is not caution, it is conviction.
Short interest tells a quieter story, and intentionally so. Bears have been retreating. Short interest fell 7% on the week to roughly 2.1% of the free float — down 10.5% over the past month — and the borrow market is essentially uninhibited, with availability running at multiples of the shares currently shorted. Cost to borrow has edged up 37% on the week to 0.55%, but that is still half a percentage point in absolute terms — not a squeeze signal. The ORTEX short score sits at 32, near the low end of its recent range. Shorts are not pressing this name.
The Street has been unmistakably constructive in the lead-up. TD Cowen lifted its target to $225 on the day of the print, the highest target on the ticker. JP Morgan moved to $201 from $181 the day prior. Piper Sandler, Morgan Stanley, Wells Fargo, and KBW all raised targets in the past two weeks — every firm maintaining a positive or at-minimum neutral rating. The mean price target now stands at $190, a step above where the previous note flagged it at $186, as further upgrades have pushed consensus higher than the current price of $184.34. The sole sceptic remains Jefferies at a $166 Hold — a valuation call on a stock that has re-rated steadily. The P/E has expanded to 11.4x, up roughly 0.7 points over the past month, and price-to-book has risen to 2.0x — modest by sector standards but moving in one direction.
The bull and bear cases have not changed shape materially. Bulls point to consistent earnings growth, diversified distribution, and the Bermuda reinsurance runway as sources of compounding. Bears anchor on interest-rate sensitivity, the pace of normalised EPS expansion, and valuation creep — Jefferies' $166 target implies an 11x multiple on 2027 estimates, which is arguably where the stock was fairly priced before the recent re-rating. The key variable now is whether the July print validates the constructive move or forces the Street to reckon with how much has already been priced in.
What to watch: the five-day reaction from here will test whether the call-heavy options positioning and the cluster of analyst upgrades correctly anticipated the numbers, or whether the stock is being asked to hold a valuation level that requires continued upside surprises to sustain.
See the live data behind this article on ORTEX.
Open GL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
